Literature DB >> 20974561

SEOM clinical guidelines for the treatment of early breast cancer.

Sonia del Barco Berrón1, Eva Ciruelos Gil, Ignacio Tusquets Trías de Bes, Montserrat Muñoz Mateu, Pedro Sánchez Rovira, Álvaro Rodríguez Lescure, Dolores Isla Casado.   

Abstract

The incidence is increasing due to mammographic screening and an ageing population. In some countries the mortality rate has decreased especially in middleaged and younger groups because of improved treatment and possibly earlier detection. However, breast cancer is still the leading cause of cancer-related death in European women. The purpose of this work was to elaborate a Spanish Society of Medical Oncology guideline on pharmacologic interventions for early breast cancer (BC). We have compiled the latest advances in the management of this pathology either in the adjuvant and neoadjuvant setting, cytostatic and hormonal treatment, so that in a simple way could be useful to oncologist, residents and other related specialties.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20974561     DOI: 10.1007/s12094-010-0584-7

Source DB:  PubMed          Journal:  Clin Transl Oncol        ISSN: 1699-048X            Impact factor:   3.405


  12 in total

1.  Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis.

Authors:  Davide Mauri; Nicholas Pavlidis; John P A Ioannidis
Journal:  J Natl Cancer Inst       Date:  2005-02-02       Impact factor: 13.506

2.  Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: an update of the initial randomized study population and data of additional patients treated with the same regimen.

Authors:  Aman U Buzdar; Vicente Valero; Nuhad K Ibrahim; Deborah Francis; Kristine R Broglio; Richard L Theriault; Lajos Pusztai; Marjorie C Green; Sonja E Singletary; Kelly K Hunt; Aysegul A Sahin; Francisco Esteva; William F Symmans; Michael S Ewer; Thomas A Buchholz; Gabriel N Hortobagyi
Journal:  Clin Cancer Res       Date:  2007-01-01       Impact factor: 12.531

3.  Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial.

Authors:  Ian E Smith; Mitch Dowsett; Stephen R Ebbs; J Michael Dixon; Anthony Skene; J-U Blohmer; Susan E Ashley; Stephen Francis; Irene Boeddinghaus; Geraldine Walsh
Journal:  J Clin Oncol       Date:  2005-07-05       Impact factor: 44.544

4.  Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks.

Authors:  Marjorie C Green; Aman U Buzdar; Terry Smith; Nuhad K Ibrahim; Vicente Valero; Marguerite F Rosales; Massimo Cristofanilli; Daniel J Booser; Lajos Pusztai; Edgardo Rivera; Richard L Theriault; Cynthia Carter; Debra Frye; Kelly K Hunt; W Fraser Symmans; Eric A Strom; Aysegul A Sahin; William Sikov; Gabriel N Hortobagyi
Journal:  J Clin Oncol       Date:  2005-08-08       Impact factor: 44.544

5.  Adjuvant docetaxel for node-positive breast cancer.

Authors:  Miguel Martin; Tadeusz Pienkowski; John Mackey; Marek Pawlicki; Jean-Paul Guastalla; Charles Weaver; Eva Tomiak; Taher Al-Tweigeri; Linnea Chap; Eva Juhos; Raymond Guevin; Anthony Howell; Tommy Fornander; John Hainsworth; Robert Coleman; Jeferson Vinholes; Manuel Modiano; Tamas Pinter; Shou C Tang; Bruce Colwell; Catherine Prady; Louise Provencher; David Walde; Alvaro Rodriguez-Lescure; Judith Hugh; Camille Loret; Matthieu Rupin; Sandra Blitz; Philip Jacobs; Michael Murawsky; Alessandro Riva; Charles Vogel
Journal:  N Engl J Med       Date:  2005-06-02       Impact factor: 91.245

6.  Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer:National Surgical Adjuvant Breast and Bowel Project Protocol B-27.

Authors:  Harry D Bear; Stewart Anderson; Roy E Smith; Charles E Geyer; Eleftherios P Mamounas; Bernard Fisher; Ann M Brown; Andre Robidoux; Richard Margolese; Morton S Kahlenberg; Soonmyung Paik; Atilla Soran; D Lawrence Wickerham; Norman Wolmark
Journal:  J Clin Oncol       Date:  2006-04-10       Impact factor: 44.544

7.  Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer.

Authors:  Stephen E Jones; Michael A Savin; Frankie Ann Holmes; Joyce A O'Shaughnessy; Joanne L Blum; Svetislava Vukelja; Kristi J McIntyre; John E Pippen; James H Bordelon; Robert Kirby; John Sandbach; William J Hyman; Pankaj Khandelwal; Angel G Negron; Donald A Richards; Stephen P Anthony; Robert G Mennel; Kristi A Boehm; Walter G Meyer; Lina Asmar
Journal:  J Clin Oncol       Date:  2006-12-01       Impact factor: 44.544

8.  Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28.

Authors:  Eleftherios P Mamounas; John Bryant; Barry Lembersky; Louis Fehrenbacher; Scot M Sedlacek; Bernard Fisher; D Lawrence Wickerham; Greg Yothers; Atilla Soran; Norman Wolmark
Journal:  J Clin Oncol       Date:  2005-05-16       Impact factor: 44.544

9.  Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer.

Authors:  Miguel Martín; Alvaro Rodríguez-Lescure; Amparo Ruiz; Emilio Alba; Lourdes Calvo; Manuel Ruiz-Borrego; Blanca Munárriz; César A Rodríguez; Carmen Crespo; Enrique de Alava; José Antonio López García-Asenjo; María Dolores Guitián; Sergio Almenar; Jesús Fernando González-Palacios; Francisco Vera; José Palacios; Manuel Ramos; Jose Manuel Gracia Marco; Ana Lluch; Isabel Alvarez; Miguel Angel Seguí; José Ignacio Mayordomo; Antonio Antón; José Manuel Baena; Arrate Plazaola; Alfonso Modolell; Amadeu Pelegrí; Jose Ramón Mel; Enrique Aranda; Encarna Adrover; José Valero Alvarez; José Luis García Puche; Pedro Sánchez-Rovira; Sonia Gonzalez; José Manuel López-Vega
Journal:  J Natl Cancer Inst       Date:  2008-05-27       Impact factor: 13.506

Review 10.  Adjuvant trastuzumab in the treatment of her-2-positive early breast cancer: a meta-analysis of published randomized trials.

Authors:  Gustavo A Viani; Sergio L Afonso; Eduardo J Stefano; Ligia I De Fendi; Francisco V Soares
Journal:  BMC Cancer       Date:  2007-08-08       Impact factor: 4.430

View more
  2 in total

1.  The relevance of the Spanish Society for Medical Oncology (SEOM)'s clinical oncology guidelines.

Authors:  Dolores Isla Casado; Antonio González-Martín; Emilio Alba Conejo
Journal:  Clin Transl Oncol       Date:  2010-11       Impact factor: 3.405

Review 2.  RELATIVE EFFECTIVENESS IN BREAST CANCER TREATMENT: A HEALTH PRODUCTION APPROACH.

Authors:  Ruth Puig-Peiro; Anne Mason; Jorge Mestre-Ferrandiz; Adrian Towse; Clare McGrath; Bengt Jonsson
Journal:  Int J Technol Assess Health Care       Date:  2016-01-20       Impact factor: 2.188

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.